New Season. Same Threat.
How Will You Help Prevent More Flu?
Influenza season has arrived and Sanofi Pasteur is offering a new series of live educational video webcasts. Presented by subject-matter experts, these webcasts will:
- Examine the medical burden of influenza and its economic impact in adults 50+ years of age
- Explore how influenza can exacerbate chronic health conditions and lead to severe outcomes, such as hospitalization and death
- Review pivotal efficacy and safety trials of Fluzone® High-Dose (Influenza Vaccine) and Flublok® Quadrivalent (Influenza Vaccine)
|Wednesday, November 14, 2018
Audrey M. Stevenson, PhD, MPH, MSN, FNP-BC
|Thursday, November 15, 2018
Robert B. Belshe, MD
INDICATION FOR FLUBLOK QUADRIVALENT AND FLUZONE HIGH-DOSE VACCINES
Flublok Quadrivalent and Fluzone High-Dose vaccines are indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B virus(es) contained in each vaccine. Flublok Quadrivalent vaccine is approved for use in persons 18 years of age and older. Fluzone High-Dose vaccine is approved for use in persons 65 years of age and older.
IMPORTANT SAFETY INFORMATION FOR FLUBLOK QUADRIVALENT AND FLUZONE HIGH-DOSE VACCINES
Flublok Quadrivalent and Fluzone High-Dose vaccines should not be administered to anyone who has had a severe allergic reaction (eg, anaphylaxis) to any component (including egg protein for Fluzone High-Dose vaccine) or previous dose of the respective vaccine. In addition, Fluzone High-Dose vaccine should not be administered to anyone who has had a severe allergic reaction to a previous dose of any influenza vaccine.
If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Flublok Quadrivalent or Fluzone High-Dose vaccine should be based on careful consideration of the potential benefits and risks.
The most common local and systemic adverse reactions to Flublok Quadrivalent and Fluzone High-Dose vaccines include pain at the injection site; headache and myalgia. Other adverse reactions may occur. Vaccination with Flublok Quadrivalent or Fluzone High-Dose vaccine may not protect all individuals.
Before administration, please see the full Prescribing Information for Fluzone High-Dose vaccine and Flublok Quadrivalent vaccine.
To order Fluzone High-Dose or Flublok Quadrivalent vaccine, go to VaccineShoppe.com or call 1-800-VACCINE (1-800-822-2463).
Fluzone High-Dose and Fluzone vaccines are manufactured and distributed by Sanofi Pasteur Inc.
Fluzone High-Dose vaccine (CPT® code 90662) is a covered benefit under Medicare Part B.
Flublok Quadrivalent vaccine is manufactured by Protein Sciences Corporation, a Sanofi company, and distributed by Sanofi Pasteur Inc.
Flublok Quadrivalent vaccine (CPT code 90682) is a covered benefit under Medicare Part B.
If you have experienced issues with streaming audio/video, please contact the webcast support desk by calling 855-341-2395
Please note that live support will be available 30 minutes prior to your program start time.